CY CYV.AX Ceryvyn Therapeutics Limited Loading... : Investor Sentiment and Bull/Bear Views

The author argues CYV.AX is mispriced because it trades at roughly negative $15m enterprise value despite about $30m cash, no debt, and only $1.1m quarterly burn, with the selloff tied to its emergence from Opthea's failed Phase 3 AMD programme. The causal mechanism is that this cash cushion plus a VEGF-C/D inhibition platform in rare disease LAM and staged continue/discontinue gates could protect downside while enabling a re-rating if Gate 1 by year-end and human data next year are positive. The author's stated main risk is simply that the programme fails, though he claims the cash balance may still allow a profit over the 12-18 month catalyst path.

CYV trades at roughly $13m market cap against ~$30m cash with no debt and only ~$1.1m quarterly burn, implying a negative enterprise value near $15m because investors wrote the company off after Opthea's failed Phase 3 AMD programme. The author claims the retained VEGF-C/D inhibition platform and a LAM rare disease programme are being valued below zero while explicit continue/discontinue gates, with Gate 1 expected by year-end and human data next year, provide multiple near-term catalysts over a 12-18 month horizon. Asymmetry comes from downside protection via the cash balance that should exceed the current market cap even after funding the initial programme, versus orphan-drug re-rating upside if data succeed. Main stated risk is straightforward programme failure, typical of biotechnology.